Table 7.

Statistical analyses of overall survival

	Overall survival
	HR	95% confidence interval	p value
Univariate analysis
Demographic
Sex (male vs female)	0.887	0.396–1.987	0.770
Age (< 60 vs 60+)	1.461	0.625–3.414	0.381
Cytogenetic/clinical factors
Risk groups (favorable vs intermediate vs adverse)	2.325	1.183–4.569	0.014
FLT3 (WT vs mutated)	1.282	0.474–3.466	0.624
Response (NR vs CR)	0.213	0.089–0.509	0.001
WBC count (low vs high)	1.168	0.514–2.650	0.711
LDH level (low vs high)	0.242	0.101–0.584	0.002
Methylation
CG6 (low vs high)	0.894	0.386–2.068	0.793
CG7 (low vs high)	0.380	0.157–0.917	0.031
CG8 (low vs high)	0.762	0.335–1.731	0.516
CG9 (low vs high)	0.331	0.136–0.805	0.015
Expression
DLK1 (low vs high)	3.212	1.096–9.413	0.033
MEG3 (low vs high)	2.294	0.819–6.421	0.114
DLK1/MEG3 (low vs high)	0.668	0.247–1.808	0.428
Multivariate analysis
Methylation
CG7 (low vs high)	0.533	0.185–1.538	0.245
CG9 (low vs high)	0.294	0.092–0.935	0.038
Expression
DLK1 (low vs high)	1.758	0.467–6.615	0.404

Low or high refers to values either lower or higher than median calculated for all AML patients included in this study. HR hazard rate, FLT3 FMS-like tyrosine kinase 3, NR non-responders, CR complete remission